CAR-T 细胞与基因治疗研发创新及生产工艺开发国际峰会2020 ( APRDL 2020 )
2020年10月15- 16日 | 上海浦东锦江汤臣洲际大酒店
会议日期：2020年10月15 -16日
会议地点：上海
往届照片：photo.html
2019峰会视频：q0872t52sr8.html
2018 峰会视频：u0666uknzn3.html
Event Information/会议信息:
Event Name: Asia Pharma R&D Leaders Summit 2020
Event Date: Oct.15 (Thur.) to 16 (Fri.).2020
Event Venue: InterContinental Shanghai Pudong Hotel
Event Link:
www.aprdl2020.com
Expected Number of Speakers: 60-70
Expected Number of Attendees: 280-300
会议名称: Asia Pharma R&D Leaders Summit 2020
会议时间: 2020年10月15-16日
会议地点: 上海浦东锦江汤臣洲际大酒店
会议网址: www.aprdl2020.com
预计演讲嘉宾人数:60-70
预计与会嘉宾人数:280-300
2020 Seminar Main Discussions
Cell Therapy Bioprocessing and Commercialization Stream
细胞治疗产品生产工艺开发及商业化进展
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions/主要议题
- Regulatory and Commercialization Considerations for Cell Therapy Products Development in China
- Cell Therapy Manufacturing Commercialization in China - Strategy and Challenges
- Cell Therapy Bioprocessing, Key CMC Strategy and Quality Control Considerations
- Breakthrough Technologies Innovation
- Automated Manufacturing of Chimeric Antigen Receptor T Cells
- Disruptive GMP Manufacturing for “Off-The-Shelf” CAR-T Cell Therapy
- CAR-T 细胞治疗产品在中国开发的法规和商业化进展
- 细胞治疗产品在中国的商业化生产面临的挑战
- 细胞治疗生产工艺技术创新与进展
- CAR-T细胞的自动化生产
- 革命性技术及创新平台在细胞治疗产品商业化过程中的应用
- 现成通用的CAR-T细胞治疗产品 在生产与质量控制过程中面临的挑战和解决方案
CAR-TCR Clinical Research and Innovation Stream
CAR-TCR细胞治疗产品临床研究及开发策略
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions/主要议题
- Surface Density of CAR Molecules Modulate the Kinetics of CAR-T Cells In Vivo
- Humanized Animal Model for CAT-T Cell Therapy Research
- Mechanisms & Clinical Study of CAR-NK Cell Drugs to Treat Solid Tumors
- Clinical Development of CAR T Cell Therapy and Next Generation
PD-1 Armored CAR-T Cells
- TCR-T Cell-based Immunotherapy for Solid Cancers
- Advancing Cancer Adoptive Immunotherapy with CRISPR/Cas9 Gene Edited T Cells
- Developing Allogeneic Cancer Immunotherapy with iPSC Technology
- 新一代抑制PD1的 “装甲” CAR-T产品的临床开发
- 将ARTEMISTM T 细胞 与TCR模拟抗体结合 治疗实体瘤
- CRISPR/Cas9
基因编辑的T细胞过继性免疫治疗的应用
- TCR-T 细胞疗法在实体瘤临床研究的应用
- 现成通用的CAR-NK细胞产品治疗实体瘤的机理及临床进展
- 人源化动物模型在CAR-T细胞疗法研究中的应用
- 运用iPSC技术来开发 同种异体癌症免疫疗法
Bio-Pharmaceutical Acceleration Development Stream
生物制品的加速开发与合作
Oct.15 (Thur.) to 16 (Fri.).2020
Main Discussions / 主要议题
- Strengthening Collaboration for Next Generation Immuno-Oncology Drug Development
- Challenges and Opportunities of Global Bio-Therapeutic Industry
- Novel Business Partnership Model for Therapeutic Biologicals
Acceleration Development in China
- Integrated Global and Local Clinical Research Strategy to Advancing Immune Oncology in China
- Revolution in Future Cancer Immunotherapy
- Perceiving the Role and Importance of Asia & China for Global Drug Development
- The Drug Marketing Authorization Holder (MAH) System in China: CMO-MAH Integration Programs Collaboration
- 下一代免疫肿瘤药品开发的创新合作模式
- 全球生物药研发的挑战与机会: 新时代新机遇新方向
- 治疗性生物制品在中国的创新加速开发及合作模式
- 通过整合全球和中国的临床研究策略来加速免疫肿瘤药品的开发
- 未来癌症免疫研究的变革
- 中国原创新药的全球临床开发的机遇与挑战
- 生物药创新趋势, MAH制度, 生物医药合同外包现状与趋势
更多关于发言, 参会及赞助方案，请联系：
联系人：Kevin Tan
联系电话：+86 21 6157 7321 / +86 1364 1961 545
Email:
kevin.tan@deliver-consulting.com
Organizing and Planning Committee | Asia Pharma R&D Leaders Summit 2020
Add: 26F, Infinitus Tower, No. 168, Hubin Road. Huangpu District, Shanghai, PR. China, 200021
